SP
The startup develops fusion proteins that target regulatory mechanisms involved in inflammatory and neuropathic pain, normalizing pain responses and inhibiting inflammation. This approach provides patients with access to pharmaceutical solutions that demonstrate efficacy in multiple pre-clinical models.
Updated 18 months ago
Funding
$20.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FIFunding rounds are not available yet.
Founders
Product
Features
- The startup develops fusion proteins that target regulatory mechanisms involved in inflammatory and neuropathic pain, normalizing pain responses and inhibiting inflammation. This approach provides patients with access to pharmaceutical solutions that demonstrate efficacy in multiple pre-clinical models.